MarketCap
Facebook
X
Telegram
Immunome Market Cap | IMNM
As of September 16, 2026 Immunome has a market cap of $ 2.09 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Immunome
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.89 B | 1.27 B | 490 M | 62.3 M | 150 M | 146 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.89 B | 62.3 M | 667 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
400 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
962 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Фармсинтез
LIFE
|
2 B | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
385 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
139 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
2.55 B | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
27 M | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
52.7 M | - | - | $ 231 M | USA |
 |
Clovis Oncology
CLVS
|
262 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
104 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
104 M | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
3.78 B | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
3.11 M | - | -9.21 % | $ 2.55 M | USA |
|
89bio
ETNB
|
976 M | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
261 M | - | - | $ 384 M | Britain |
 |
Fusion Pharmaceuticals
FUSN
|
1.38 B | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
7.1 M | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
72.7 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
276 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
173 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
21.6 M | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
12.5 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
6.71 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
706 M | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
84.7 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
6.84 M | - | - | $ 13.1 M | Canada |
 |
Intra-Cellular Therapies
ITCI
|
13.3 B | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
124 M | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
1.39 B | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
73.7 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
69.3 M | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
11.8 B | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
48.1 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
127 M | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
74.8 M | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
24.6 M | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
211 M | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
450 M | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
2.56 B | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
3.64 M | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
17.5 M | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
3.15 M | - | -37.48 % | $ 476 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
18.7 M | - | -19.68 % | $ 18.4 M | Canada |
 |
ObsEva SA
OBSV
|
156 M | - | -15.52 % | $ 10.5 M | Schweiz |
 |
Oncorus
ONCR
|
8.55 K | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
17.7 M | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
27.3 M | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
117 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
672 M | - | 1.02 % | $ 90.8 M | Britain |